Skip to content
LATEST
Health

Federal Government Allocates $4.9 Million for Ibogaine Research

The federal government is providing $4.9 million to develop clinical research protocols for ibogaine, a restricted psychedelic, to address PTSD among veterans.

Federal Government Allocates $4.9 Million for Ibogaine Research

The Department of Health and Human Services has announced an allocation of up to $4.9 million to initiate preparatory research into the medical efficacy of ibogaine. This funding is designated for the development of manufacturing protocols, dosing standards, and clinical trial design rather than direct patient administration. The initiative aims to address post-traumatic stress disorder (PTSD) among veterans, a demographic identified as having elevated risks for suicide and substance abuse.

Ibogaine is currently classified as a Schedule I controlled substance, placing it in the same regulatory category as LSD and MDMA. Due to its potential for severe side effects, including cardiac arrhythmias, nausea, and intense hallucinations, domestic research has been historically limited. The government intends to leverage existing clinical data from a private entity, Beond Inc., which has administered the substance in international jurisdictions where it is not prohibited.

The Department

This research directive follows an executive order signed in April 2026, which mandated that federal agencies accelerate the review and study of psychedelic substances for mental health applications. The Department of Veterans Affairs is collaborating on the project, emphasizing a focus on safety protocols and clinical rigor. Officials have indicated that this partnership is intended to expedite the regulatory approval process for future therapeutic use.

The administration is currently reviewing three separate applications for other psychedelic-based medicines, including psilocybin and MDMA, with decisions expected in the near term. While the current funding is focused on PTSD, officials suggested that subsequent awards may explore the drug's potential utility in treating addiction. The shift in federal policy reflects a broader effort to integrate alternative substances into the standard of care for veterans, despite the significant safety profile and regulatory hurdles associated with these compounds.

More stories

Latest news